Skip to main content
. 2020 Sep 4;12(9):2521. doi: 10.3390/cancers12092521

Figure 3.

Figure 3

Molecular Recurrence-free survival (MRFS) (N = 83 pts). (A): all patients, (B): according to first-line TKI (Imatinib vs. 2nd or 3rd generation TKI), (C): according to first-line TKIs (Imatinib vs. 2nd or 3rd generation TKI) and history of switch for intolerance or insufficient efficacy (failure or warning as defined in the 2013 ELN recommendations [26]).